$BMEA News

Citizens Reiterates Market Outperform on Biomea Fusion, Maintains $7 Price Target

HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $4 Price Target

What’s Going On With Biomea Fusion (BMEA) Stock After Hours?

Biomea Fusion’s BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss - Slideshow

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

Biomea Fusion BMF-650 Phase 1 Weight Loss Results Remain Preliminary, With Longer-Term Trials And Toxicology Studies Still Outstanding

Biomea Fusion Reports Phase 1 Results For Oral GLP-1 Candidate BMF-650, Showing Consistent Weight Reduction And Encouraging Tolerability

Biomea Fusion Stock Climbs 7% After-Hours: What's Going On?

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

Biomea Fusion To Report Results From Phase I GLP-131 Clinical Study Evaluating BMF-650, Investigational Next-Gen Oral Small-Molecule GLP-1 Receptor Agonist, On October 13

Brookline Capital Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $10

Biomea Pulls Equity Raise, Trading Dilution Relief For Near-Term Runway Pressure

Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

Biomea Fusion Terminates Proposed Public Offering Of Securities Due To Market Conditions

Biomea Fusion Shares Fall 19% After Hours: Here’s Why

Biomea Fusion Announces Proposed Public Offering of Securities

Biomea Fusion Says Topline Data From Phase 1 Obesity Trial Of BMF-650 Now Expected In October, Pushed From Q3